This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ofloxacin ocular


Ophthalmic solution containing ofloxacin

Drugs List

  • EXOCIN 0.3% eye drops
  • ofloxacin 0.3% eye drops
  • Therapeutic Indications


    Eye infection - topical treatment



    Instil one to two drop(s) into the affected eye(s) every 2 to 4 hours for the initial two days and then decrease to four times a day thereafter, up to a maximum of 10 days.


    Instil one to two drop(s) into the affected eye(s) every 2 to 4 hours for the initial two days and then decrease to four times a day thereafter, up to a maximum of 10 days.


    Children over 1 year
    Instil one to two drop(s) into the affected eye(s) every 2 to 4 hours for the initial two days and then decrease to four times a day thereafter, up to a maximum of 10 days.

    Children under 1 year
    Not recommended.


    It is not recommended to use ofloxacin eye drops 0.3% in neonates when treating ophthalmia neonatorum caused by Neisseria gonorrhoeae or chlamydia trachomatis as it has not been evaluated.


    Children under 1 year
    Wearing of contact lenses

    Precautions and Warnings

    Corneal damage
    Dry eyes

    Advise patient blurred vision may affect ability to drive/operate machinery
    Contains benzalkonium chloride
    To reduce systemic absorption compress lacrimal sac during administration
    Monitor patients on prolonged therapy
    Prolonged use may result in superinfection with non-susceptible organisms
    Discontinue treatment if any infection worsens
    Discontinue treatment if skin rash or other allergic reaction occurs
    Length of treatment should not exceed 10 days
    Advise patient not to use for 5 mins after applying any other ocular agent
    Advise patient to avoid exposure to sunlight and UV rays during treatment
    Advise patient to avoid touching the eye/other surfaces with container tip
    Contact lenses should not be worn during treatment
    Discolours soft contact lenses
    Remove contact lenses before use and re-insert 15 minutes after use

    Pregnancy and Lactation


    UK licensed product information recommends that ofloxacin eye drops should not be used during pregnancy. There is limited data on the use of quinolone antibiotic eye drops during pregnancy.

    Quinolones have a high affinity for cartilage and bone tissue, this affinity is highest in immature cartilage. Ofloxacin is known to cross the placenta. Systemic quinolones have been shown to cause arthropathy in several animal species after administration in-utero and to immature animals. The use of systemic quinolones during human pregnancy has not been associated with an increase in the risk of major congenital malformations. A casual relationship with some of the birth defects noted in case studies cannot be excluded. In view of this and the known adverse effects in animals, fluoroquinolones should be avoided during pregnancy wherever possible, but if compellingly indicated, ciprofloxacin has a relatively large documented experience. Schaefer concludes that even first trimester exposure to systemic treatment is not an indication for termination of pregnancy but recommends offering detailed foetal ultrasonography.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    UK licensed product information recommends that ofloxacin should not be used during breastfeeding and when use is judged essential, the manufacturers advise discontinuation of breast feeding whilst on therapy.

    There is limited data on the use of quinolone antibiotic eye drops during breastfeeding. Ofloxacin is secreted in milk. Systemic ofloxacin has not been routinely used in children because of concern about arthropathy noted in the joints of young animals. Systemic quinolones should not routinely be used during breastfeeding where an antibiotic with a lower risk profile can be chosen. Most authorities consider that when treatment of a complicated infection necessitates use, a quinolone, preferably ciprofloxacin (for which there is the greatest experience), may be chosen.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Anaphylactic reaction
    Anaphylactic shock
    Blurred vision (transient)
    Dry eyes
    Eyelid pruritus
    Facial oedema
    Hypersensitivity reactions
    Increased lacrimation
    Ocular hyperaemia
    Ocular irritation
    Ocular oedema
    Ocular pain
    Ocular pruritus
    Oropharyngeal swelling
    Periorbital oedema
    Sensation of foreign body in eye
    Stevens-Johnson syndrome
    Tongue swelling
    Torsades de pointes
    Toxic epidermal necrolysis
    Transient ocular discomfort
    Ventricular arrhythmias


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2013.

    Reference Sources

    British National Formulary, 65th Edition (March - September 2013) Pharmaceutical Press, London.

    BNF for Children (2013-2014) Pharmaceutical Press, London.

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications [Accessed on 16.10.13].

    Summary of Product Characteristics: Exocin 3mg/ml eye drops solution. Allergan Ltd. Revised September 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.